OA12200A - Polymorphs of N-methyl-N-(3-ä3-Ä2-thienylcarbonylÜ-pyrazol-Ä1-5-aÜ-pyrimidin-7-YLüphenyl)acetamide and compositions and methods related thereto. - Google Patents

Polymorphs of N-methyl-N-(3-ä3-Ä2-thienylcarbonylÜ-pyrazol-Ä1-5-aÜ-pyrimidin-7-YLüphenyl)acetamide and compositions and methods related thereto. Download PDF

Info

Publication number: OA12200A
Authority: OA; OAPI
Prior art keywords: polymorph; pyrimidin; methyl; substantially pure; acetamide
Prior art date: 1999-09-02

Application number

OA1200200057A

Other languages

English (en)

Inventor

William J Thiele

Patrick B O'donnell

Original Assignee

Neurocrine Biosciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-02

Filing date

2000-09-01

Publication date

2006-05-09

2000-09-01 Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc

2006-05-09 Publication of OA12200A publication Critical patent/OA12200A/en

Links

238000000034 method Methods 0.000 title claims abstract description 82
239000000203 mixture Substances 0.000 title claims abstract description 61
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 title claims abstract description 14
230000008569 process Effects 0.000 claims abstract description 53
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims abstract description 17
206010022437 insomnia Diseases 0.000 claims abstract description 16
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 45
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 43
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 36
239000002904 solvent Substances 0.000 claims description 32
238000002425 crystallisation Methods 0.000 claims description 25
230000008025 crystallization Effects 0.000 claims description 25
239000013078 crystal Substances 0.000 claims description 20
238000010438 heat treatment Methods 0.000 claims description 19
239000007787 solid Substances 0.000 claims description 18
238000001816 cooling Methods 0.000 claims description 17
238000002844 melting Methods 0.000 claims description 17
230000008018 melting Effects 0.000 claims description 17
239000006184 cosolvent Substances 0.000 claims description 16
239000003960 organic solvent Substances 0.000 claims description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
238000004467 single crystal X-ray diffraction Methods 0.000 claims description 9
230000000694 effects Effects 0.000 claims description 8
239000012535 impurity Substances 0.000 claims description 8
230000001939 inductive effect Effects 0.000 claims description 8
230000000147 hypnotic effect Effects 0.000 claims description 7
230000007958 sleep Effects 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 6
239000006187 pill Substances 0.000 claims description 5
239000002775 capsule Substances 0.000 claims description 4
238000003801 milling Methods 0.000 claims description 4
210000002027 skeletal muscle Anatomy 0.000 claims description 4
239000003826 tablet Substances 0.000 claims description 4
238000004090 dissolution Methods 0.000 claims description 3
239000002245 particle Substances 0.000 claims description 3
206010021118 Hypotonia Diseases 0.000 claims 2
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 2
239000012141 concentrate Substances 0.000 claims 2
239000002552 dosage form Substances 0.000 claims 2
238000001035 drying Methods 0.000 claims 2
230000001747 exhibiting effect Effects 0.000 claims 2
230000036640 muscle relaxation Effects 0.000 claims 2
238000002050 diffraction method Methods 0.000 claims 1
239000012530 fluid Substances 0.000 claims 1
230000035876 healing Effects 0.000 claims 1
150000001875 compounds Chemical class 0.000 abstract description 22
239000002249 anxiolytic agent Substances 0.000 abstract description 4
230000000949 anxiolytic effect Effects 0.000 abstract description 3
230000001773 anti-convulsant effect Effects 0.000 abstract description 2
239000001961 anticonvulsive agent Substances 0.000 abstract description 2
230000004799 sedative–hypnotic effect Effects 0.000 abstract description 2
229940125681 anticonvulsant agent Drugs 0.000 abstract 1
229940125706 skeletal muscle relaxant agent Drugs 0.000 abstract 1
229940125904 compound 1 Drugs 0.000 description 50
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 23
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
238000001938 differential scanning calorimetry curve Methods 0.000 description 16
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
125000004429 atom Chemical group 0.000 description 9
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical class N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 8
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 8
238000001914 filtration Methods 0.000 description 8
239000011541 reaction mixture Substances 0.000 description 8
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 7
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
238000002290 gas chromatography-mass spectrometry Methods 0.000 description 6
239000003326 hypnotic agent Substances 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
240000007124 Brassica oleracea Species 0.000 description 5
235000003899 Brassica oleracea var acephala Nutrition 0.000 description 5
235000012905 Brassica oleracea var viridis Nutrition 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 5
229910052757 nitrogen Inorganic materials 0.000 description 5
239000008194 pharmaceutical composition Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
238000001757 thermogravimetry curve Methods 0.000 description 5
ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 4
229940125717 barbiturate Drugs 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 3
230000008901 benefit Effects 0.000 description 3
-1 benzodiazépine GABA complexes Chemical class 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
238000013500 data storage Methods 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
238000010316 high energy milling Methods 0.000 description 3
239000001257 hydrogen Substances 0.000 description 3
229910052739 hydrogen Inorganic materials 0.000 description 3
238000001228 spectrum Methods 0.000 description 3
SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 2
WYJOVVXUZNRJQY-UHFFFAOYSA-N 2-Acetylthiophene Chemical compound CC(=O)C1=CC=CS1 WYJOVVXUZNRJQY-UHFFFAOYSA-N 0.000 description 2
NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 description 2
RRLMPLDPCKRASL-UHFFFAOYSA-N 3-(dimethylamino)prop-2-enal Chemical class CN(C)C=CC=O RRLMPLDPCKRASL-UHFFFAOYSA-N 0.000 description 2
BAKYASSDAXQKKY-UHFFFAOYSA-N 4-Hydroxy-3-methylbenzaldehyde Chemical compound CC1=CC(C=O)=CC=C1O BAKYASSDAXQKKY-UHFFFAOYSA-N 0.000 description 2
208000019901 Anxiety disease Diseases 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
208000034189 Sclerosis Diseases 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
208000012886 Vertigo Diseases 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000000496 anti-anoxic effect Effects 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
230000006399 behavior Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000003874 central nervous system depressant Substances 0.000 description 2
238000005056 compaction Methods 0.000 description 2
229940126214 compound 3 Drugs 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
238000000113 differential scanning calorimetry Methods 0.000 description 2
238000004821 distillation Methods 0.000 description 2
230000001037 epileptic effect Effects 0.000 description 2
239000008187 granular material Substances 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
239000012452 mother liquor Substances 0.000 description 2
230000000926 neurological effect Effects 0.000 description 2
239000003921 oil Substances 0.000 description 2
239000002798 polar solvent Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
239000003586 protic polar solvent Substances 0.000 description 2
238000010992 reflux Methods 0.000 description 2
208000019116 sleep disease Diseases 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000007910 systemic administration Methods 0.000 description 2
231100000889 vertigo Toxicity 0.000 description 2
QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
XWSCOGPKWVNQSV-UHFFFAOYSA-N 5-bromo-2,3-dichloropyridine Chemical compound ClC1=CC(Br)=CN=C1Cl XWSCOGPKWVNQSV-UHFFFAOYSA-N 0.000 description 1
101150041968 CDC13 gene Proteins 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
206010019133 Hangover Diseases 0.000 description 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
206010024264 Lethargy Diseases 0.000 description 1
229910017912 NH2OH Inorganic materials 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
230000032683 aging Effects 0.000 description 1
229940094070 ambien Drugs 0.000 description 1
230000001668 ameliorated effect Effects 0.000 description 1
238000004164 analytical calibration Methods 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
239000000010 aprotic solvent Substances 0.000 description 1
238000010420 art technique Methods 0.000 description 1
METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
230000001914 calming effect Effects 0.000 description 1
238000007707 calorimetry Methods 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
229960002327 chloral hydrate Drugs 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
229940125898 compound 5 Drugs 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
229960003692 gamma aminobutyric acid Drugs 0.000 description 1
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
239000007789 gas Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
239000012456 homogeneous solution Substances 0.000 description 1
239000005554 hypnotics and sedatives Substances 0.000 description 1
239000005457 ice water Substances 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
238000007726 management method Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
206010027175 memory impairment Diseases 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
230000000116 mitigating effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
230000036651 mood Effects 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
AFZTYHRVDOKRKV-UHFFFAOYSA-N n-(3-acetylphenyl)acetamide Chemical compound CC(=O)NC1=CC=CC(C(C)=O)=C1 AFZTYHRVDOKRKV-UHFFFAOYSA-N 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
239000012454 non-polar solvent Substances 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
239000010502 orange oil Substances 0.000 description 1
230000008447 perception Effects 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
229940068918 polyethylene glycol 400 Drugs 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000002002 slurry Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
229940061368 sonata Drugs 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000005062 synaptic transmission Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000008719 thickening Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000003966 vascular damage Effects 0.000 description 1
239000003039 volatile agent Substances 0.000 description 1
238000002424 x-ray crystallography Methods 0.000 description 1
229960004010 zaleplon Drugs 0.000 description 1
HUNXMJYCHXQEGX-UHFFFAOYSA-N zaleplon Chemical compound CCN(C(C)=O)C1=CC=CC(C=2N3N=CC(=C3N=CC=2)C#N)=C1 HUNXMJYCHXQEGX-UHFFFAOYSA-N 0.000 description 1
ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1
229960005111 zolpidem tartrate Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Neurology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)
Plural Heterocyclic Compounds (AREA)

OA1200200057A 1999-09-02 2000-09-01 Polymorphs of N-methyl-N-(3-ä3-Ä2-thienylcarbonylÜ-pyrazol-Ä1-5-aÜ-pyrimidin-7-YLüphenyl)acetamide and compositions and methods related thereto. OA12200A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US38952499A	1999-09-02	1999-09-02
US42162099A	1999-10-19	1999-10-19

Publications (1)

Publication Number	Publication Date
OA12200A true OA12200A (en)	2006-05-09

Family

ID=27012737

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200200057A OA12200A (en)	1999-09-02	2000-09-01	Polymorphs of N-methyl-N-(3-ä3-Ä2-thienylcarbonylÜ-pyrazol-Ä1-5-aÜ-pyrimidin-7-YLüphenyl)acetamide and compositions and methods related thereto.

Country Status (26)

Country	Link
EP (2)	EP1477169A1 (fr)
JP (1)	JP4592241B2 (fr)
KR (1)	KR20020035585A (fr)
CN (2)	CN1331865C (fr)
AP (1)	AP1631A (fr)
AT (1)	ATE269082T1 (fr)
AU (2)	AU769856B2 (fr)
BR (1)	BR0014459A (fr)
CA (1)	CA2382588C (fr)
CZ (1)	CZ2002783A3 (fr)
DE (1)	DE60011638T2 (fr)
DK (1)	DK1214075T3 (fr)
EA (1)	EA004706B1 (fr)
ES (1)	ES2222920T3 (fr)
HK (1)	HK1047407B (fr)
HU (1)	HUP0202698A3 (fr)
IL (2)	IL148242A0 (fr)
MX (1)	MXPA02002314A (fr)
NO (1)	NO322752B1 (fr)
NZ (1)	NZ517298A (fr)
OA (1)	OA12200A (fr)
PL (1)	PL353362A1 (fr)
PT (1)	PT1214075E (fr)
SK (1)	SK2782002A3 (fr)
TR (1)	TR200200534T2 (fr)
WO (1)	WO2001015700A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MXPA05002251A (es)	2002-08-26	2005-06-08	Neurocrine Biosciences Inc	Polimorfo novedoso del n- metil -n- (3- {3-[2- tienilcarbonil] -pirazol -[1, 5-(alfa)] -pirimidina- 7-yl} fenil) acetamida y composiciones y metodos relacionados.
WO2004110454A1 (fr) *	2003-06-13	2004-12-23	Ishihara Sangyo Kaisha, Ltd.	Composition de traitement ou de prevention de maladies necessitant l'administration d'un agoniste du recepteur a2a de l'adenosine
US7371906B2 (en) *	2004-08-24	2008-05-13	Eastman Kodak Company	Process for photo-oxidative stability improvements
EP1956021A1 (fr) *	2006-10-11	2008-08-13	Ferrer Internacional, S.A.	Procédé de préparation d'un pyrazole[1,5-a]pyrimidine en forme crystalline
EP1918290A1 (fr)	2006-10-11	2008-05-07	Ferrer Internacional, S.A.	La polymorphe B de la N-{2-fluoro-5-[3-thiophèn-2-carbonyle)-pyrazolo[1,5-a]pyrimidin-7-yl]-phènyl}-N-methyle-acetamide
CN101177427B (zh) *	2006-11-09	2011-07-20	中国人民解放军军事医学科学院放射与辐射医学研究所	一种用于催眠的化合物的多晶型α和溶剂化物,其制备方法及含该物质的组合物
US20120028045A1 (en) *	2009-03-24	2012-02-02	Glenmark Generics Ltd	Processes for the Preparation of Indiplon and Intermediates Thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ208554A (en) *	1983-06-23	1987-06-30	American Cyanamid Co	(aryl and heteroaryl)-(7-(aryl and heteroaryl)-pyrazolo (1,5-a) pyrimidin-3-yl)-methanone derivatives and pharmaceutical compositions
US4521422A (en) *	1983-06-23	1985-06-04	American Cyanamid Company	Aryl and heteroaryl[7-(aryl and heteroaryl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones
US4654347A (en) *	1983-06-23	1987-03-31	American Cyanamid Company	Aryl and heteroaryl[[7-(3-disubstituted amino)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanones
US4626538A (en) *	1983-06-23	1986-12-02	American Cyanamid Company	[7-(3-disubstituted amino)phenyl]pyrazolo[1,5-a]pyrimidines
DE19975048I2 (de) *	1985-05-13	2001-06-13	American Cyanamid Co	7-(3-Disubstituierte Amino)phenyl pyrazolo 1,5-a -pyrimidine
US5421422A (en) *	1993-11-19	1995-06-06	Boretec Inc	Roller cutter mount for tunneling machine

2000
- 2000-09-01 EP EP04013998A patent/EP1477169A1/fr not_active Withdrawn
- 2000-09-01 DK DK00957941T patent/DK1214075T3/da active
- 2000-09-01 AU AU69491/00A patent/AU769856B2/en not_active Ceased
- 2000-09-01 ES ES00957941T patent/ES2222920T3/es not_active Expired - Lifetime
- 2000-09-01 DE DE60011638T patent/DE60011638T2/de not_active Expired - Lifetime
- 2000-09-01 AP APAP/P/2002/002428A patent/AP1631A/en active
- 2000-09-01 CA CA002382588A patent/CA2382588C/fr not_active Expired - Fee Related
- 2000-09-01 HU HU0202698A patent/HUP0202698A3/hu unknown
- 2000-09-01 KR KR1020027002829A patent/KR20020035585A/ko not_active Ceased
- 2000-09-01 TR TR2002/00534T patent/TR200200534T2/xx unknown
- 2000-09-01 JP JP2001519914A patent/JP4592241B2/ja not_active Expired - Lifetime
- 2000-09-01 OA OA1200200057A patent/OA12200A/en unknown
- 2000-09-01 EP EP00957941A patent/EP1214075B1/fr not_active Expired - Lifetime
- 2000-09-01 CN CNB2005100545485A patent/CN1331865C/zh not_active Expired - Fee Related
- 2000-09-01 IL IL14824200A patent/IL148242A0/xx active IP Right Grant
- 2000-09-01 AT AT00957941T patent/ATE269082T1/de active
- 2000-09-01 CN CNB008131589A patent/CN1198824C/zh not_active Expired - Fee Related
- 2000-09-01 PT PT00957941T patent/PT1214075E/pt unknown
- 2000-09-01 WO PCT/US2000/024051 patent/WO2001015700A1/fr not_active Ceased
- 2000-09-01 HK HK02109094.4A patent/HK1047407B/en not_active IP Right Cessation
- 2000-09-01 SK SK278-2002A patent/SK2782002A3/sk unknown
- 2000-09-01 NZ NZ517298A patent/NZ517298A/en not_active IP Right Cessation
- 2000-09-01 BR BR0014459-2A patent/BR0014459A/pt not_active Application Discontinuation
- 2000-09-01 MX MXPA02002314A patent/MXPA02002314A/es active IP Right Grant
- 2000-09-01 CZ CZ2002783A patent/CZ2002783A3/cs unknown
- 2000-09-01 PL PL00353362A patent/PL353362A1/xx not_active Application Discontinuation
- 2000-09-01 EA EA200200320A patent/EA004706B1/ru not_active IP Right Cessation
2002
- 2002-02-19 IL IL148242A patent/IL148242A/en not_active IP Right Cessation
- 2002-03-01 NO NO20021041A patent/NO322752B1/no not_active IP Right Cessation
2004
- 2004-03-31 AU AU2004201356A patent/AU2004201356A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HK1047407B (en)	2004-12-24
KR20020035585A (ko)	2002-05-11
HUP0202698A2 (hu)	2002-12-28
MXPA02002314A (es)	2002-08-12
SK2782002A3 (en)	2003-04-01
CA2382588C (fr)	2008-11-25
IL148242A0 (en)	2002-09-12
HUP0202698A3 (en)	2004-12-28
AU6949100A (en)	2001-03-26
NO20021041D0 (no)	2002-03-01
PL353362A1 (en)	2003-11-17
ATE269082T1 (de)	2004-07-15
NO322752B1 (no)	2006-12-04
ES2222920T3 (es)	2005-02-16
CN1374866A (zh)	2002-10-16
AU769856B2 (en)	2004-02-05
EP1477169A1 (fr)	2004-11-17
IL148242A (en)	2006-12-10
DE60011638T2 (de)	2004-10-21
WO2001015700A1 (fr)	2001-03-08
EP1214075B1 (fr)	2004-06-16
JP4592241B2 (ja)	2010-12-01
CN1198824C (zh)	2005-04-27
DK1214075T3 (da)	2004-10-25
PT1214075E (pt)	2004-11-30
NO20021041L (no)	2002-04-03
EA004706B1 (ru)	2004-06-24
AP1631A (en)	2006-07-12
AP2002002428A0 (en)	2002-03-31
CN1331865C (zh)	2007-08-15
CZ2002783A3 (cs)	2004-01-14
JP2003508440A (ja)	2003-03-04
BR0014459A (pt)	2002-07-16
EA200200320A1 (ru)	2002-08-29
DE60011638D1 (de)	2004-07-22
HK1047407A1 (en)	2003-02-21
EP1214075A1 (fr)	2002-06-19
CA2382588A1 (fr)	2001-03-08
CN1680376A (zh)	2005-10-12
EP1214075A4 (fr)	2003-05-02
TR200200534T2 (tr)	2002-06-21
NZ517298A (en)	2004-01-30
WO2001015700A9 (fr)	2002-09-12
AU2004201356A1 (en)	2004-04-29

Publication	Publication Date	Title
US6903106B2 (en)	2005-06-07	Polymorph of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
US6384221B1 (en)	2002-05-07	Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
OA12200A (en)	2006-05-09	Polymorphs of N-methyl-N-(3-ä3-Ä2-thienylcarbonylÜ-pyrazol-Ä1-5-aÜ-pyrimidin-7-YLüphenyl)acetamide and compositions and methods related thereto.
HK1071077A (en)	2005-07-08	Reactions of polymorphs of n-methyl-n-(3-(3-(2-thienylcarbonyl)-pyrazol-(1,5-alpha)-pyrimidin-7-yl)phenyl)acetamide
HK1071373B (en)	2007-05-25	Novel polymorph of n-methyl-n-(3- 3- 2-thienylcarbonyl-pyrazol- 1,5-alpha-pyrimidin-7-yl phenyl)acetamide and compositions and methods related thereto